WBB Securities Acts as Co-manager to TetraLogic Pharmaceuticals on $47MM Convertible Senior Notes Transaction
Posted: Jun 25th, 2014In: Press ReleasesWBB Securities acted as co-manager on a convertible senior notes transaction for TetraLogic Pharmaceuticals, Inc.
Read More about WBB Securities Acts as Co-manager to TetraLogic Pharmaceuticals on $47MM Convertible Senior Notes TransactionWBB Securities Acts as Exclusive Placement Agent to Cytori Therapeutics
Posted: Jun 6th, 2014In: Press ReleasesWBB Securities acted as exclusive placement agent on a registered direct financing for Cytori Therapeutics, a clinical phase regenerative medicine company.
Read More about WBB Securities Acts as Exclusive Placement Agent to Cytori TherapeuticsWBB Securities Named Co-Manager on Omeros Corporation Underwriting
Posted: Mar 19th, 2014In: Press ReleasesOmeros closes $40.25 million in underwritten public offering
Read More about WBB Securities Named Co-Manager on Omeros Corporation UnderwritingWBB Securities Retained as Financial Advisor to Athersys, Inc.
Posted: Jan 10th, 2014In: Press ReleasesAthersys announces $20.5 million registered direct financing to fund ongoing clinical trials in regenerative medicine
Read More about WBB Securities Retained as Financial Advisor to Athersys, Inc.WBB Securities Sponsors BioCentury’s 20th Annual NewsMakers Conference
Posted: Oct 1st, 2013In: Press ReleasesExecutive Teams of Emerging Biotech Companies to Present to Investor Community
Read More about WBB Securities Sponsors BioCentury’s 20th Annual NewsMakers ConferenceFinancial Times and Thomson Reuters name Steve Brozak as a 2013 StarMine
Posted: Aug 22nd, 2013In: Press ReleasesWBB's Steve Brozak named "Top Stock Picker" in Pharmaceuticals
Read More about Financial Times and Thomson Reuters name Steve Brozak as a 2013 StarMineWBB Securities Retained as Financial Advisor to Navidea Biopharmaceuticals, Inc.
Posted: Jun 26th, 2013In: Press ReleasesNavidea closes $25 million debt financing with GE Capital to finance and manage commercialization of approved radiopharmaceutical
Read More about WBB Securities Retained as Financial Advisor to Navidea Biopharmaceuticals, Inc.WBB Securities Retained as Financial Advisor to Cempra, Inc.
Posted: Jun 19th, 2013In: Press ReleasesCempra closes $54.2 million financing to support its efforts to develop and commercialize novel antibiotic treatments
Read More about WBB Securities Retained as Financial Advisor to Cempra, Inc.WBB Sponsors 2013 BIO CEO
Posted: Feb 1st, 2013In: Press ReleasesConference is focused on established and emerging publicly traded and select private biotech companies
Read More about WBB Sponsors 2013 BIO CEOWBB Securities’ Steve Brozak Speaks on Drug Development Costs at Bloomberg Healthcare Innovations Conference
Posted: Oct 2nd, 2012In: Press ReleasesBloomberg Healthcare Conference aims to identify promising innovations in the healthcare space
Read More about WBB Securities’ Steve Brozak Speaks on Drug Development Costs at Bloomberg Healthcare Innovations Conference